What top creators are saying about Whoop(PRIVATE)

Recurring revenue, member engagement, extensive physiological data, and AI development may support an investment thesis, but profitability and valuation attractiveness are unproven. Risks include regulatory disagreements and competition from Apple.

Recurring subscriptions, high engagement, and physiological data may support product development and retention, but profitability and valuation are unverified; FDA oversight and sensitive-data handling are important considerations.

Mentioned as an example of a consumer device brand that tracks sleep and physiology, without a specific investment recommendation or company assessment.

Mentioned as an example of a wearable measuring sleep-related data such as heart rate and HRV. No investment recommendation or financial analysis was provided.

Whoop was mentioned as a source of wearable health data; the discussion focused on integrating such data with clinical tests and offered no investment recommendation.

Whoop's personalized metrics may encourage habit changes and support subscription demand, but the reported benefits are anecdotal and the scores may cause anxiety; the company could go public, with no IPO timing or valuation specified.

Polygon's founder, Sandeep Nailwal, expressed extreme bullishness, stating he passed on investing at a $3.2B valuation and now believes it is a 'hundred billion dollar company' in the making.